中国心脏起搏与心电生理杂志

1 Van Gelder IC,Rienstra M,Bunting KV,et al.2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)[J].Eur Heart J,2024:ehae176.doi:10.1093/eurheartj/ehae176

2 De With RR,Erküner ?,Rienstra M,et al.Temporal patterns and short-term progression of paroxysmal atrial fibrillation:data from RACE V[J].Europace,2020,22(8):1 162

3 Packer DL,Mark DB,Robb RA,et al.Effect of catheter ablation vs antiarrhythmic drug therapy on mortality,stroke,bleeding,and cardiac arrest among patients with atrial fibrillation:the CABANA randomized clinical trial[J].JAMA,2019,321(13):1 261

4 Marrouche NF,Brachmann J,Andresen D,et al.Catheter ablation for atrial fibrillation with heart failure[J].N Engl J Med,2018,378(5):417

5 Rienstra M,Hobbelt AH,Alings M,et al.Targeted therapy of underlying conditions improves sinus rhythm maintenance in patients with persistent atrial fibrillation:results of the RACE 3 trial[J].Eur Heart J,2018,39(32):2 987

6 Abed HS,Wittert GA,Leong DP,et al.Effect of weight reduction and cardiometabolic risk factor management on symptom burden and severity in patients with atrial fibrillation:a randomized clinical trial[J].JAMA,2013,310(19):2 050

7 Pathak RK,Middeldorp ME,Meredith M,et al.Long-term effect of goal-directed weight management in an atrial fibrillation cohort:a long-term follow-up study (LEGACY)[J].J Am Coll Cardiol,2015,65(20):2 159

8 Middeldorp ME,Pathak RK,Meredith M,et al.PREVEntion and regReSsive effect of weight-loss and risk factor modification on atrial fibrillation:the REVERSE-AF study[J].Europace,2018,20(6):1 929

9 Pathak RK,Middeldorp ME,Lau DH,et al.Aggressive risk factor reduction study for atrial fibrillation and implications for the outcome of ablation:the ARREST-AF cohort study[J].J Am Coll Cardiol,2014,64(21):2 222

10 Pinho-Gomes AC,Azevedo L,Copland E,et al.Blood pressure-lowering treatment for the prevention of cardiovascular events in patients with atrial fibrillation:an individual participant data meta-analysis[J].PLoS Med,2021,18(6):e1 003 599

11 Parkash R,Wells GA,Sapp JL,et al.Effect of aggressive blood pressure control on the recurrence of atrial fibrillation after catheter ablation:a randomized,open-label clinical trial (SMAC-AF [Substrate Modification with Aggressive Blood Pressure Control])[J].Circulation,2017,135(19):1 788

12 McMurray JJ,Adamopoulos S,Anker SD,et al.ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012:the task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European Society of Cardiology.Developed in collaboration with the Heart Failure Association (HFA) of the ESC[J].Eur Heart J,2012,33(14):1 787

13 Olsson LG,Swedberg K,Ducharme A,et al.Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction:results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program[J].J Am Coll Cardiol,2006,47(10):1 997

14 Kotecha D,Holmes J,Krum H,et al.Efficacy of beta blockers in patients with heart failure plus atrial fibrillation:an individual-patient data meta-analysis[J].Lancet,2014,384(9961):2 235

15 Zannad F,McMurray JJ,Krum H,et al.Eplerenone in patients with systolic heart failure and mild symptoms[J].N Engl J Med,2011,364(1):11

16 McMurray JJ,Packer M,Desai AS,et al.Angiotensin-neprilysin inhibition versus enalapril in heart failure[J].N Engl J Med,2014,371(11):993

17 Pandey AK,Okaj I,Kaur H,et al.Sodium-glucose co-transporter inhibitors and atrial fibrillation:a systematic review and meta-analysis of randomized controlled trials[J].J Am Heart Assoc,2021,10(17):e 022 222

18 McDonagh TA,Metra M,Adamo M,et al.2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure[J].Eur Heart J,2021,42(36):3 599

19 Solomon SD,McMurray JJV,Claggett B,et al.Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction[J].N Engl J Med,2022,387(12):1 089

20 Anker SD,Butler J,Filippatos G,et al.Empagliflozin in heart failure with a preserved ejection fraction[J].N Engl J Med,2021,385(16):1 451

21 Bhatt DL,Szarek M,Steg PG,et al.Sotagliflozin in patients with diabetes and recent worsening heart failure[J].N Engl J Med,2021,384(2):117

22 Pathak RK,Elliott A,Middeldorp ME,et al.Impact of CARDIOrespiratory FITness on arrhythmia recurrence in obese individuals with atrial fibrillation:the CARDIO-FIT study[J].J Am Coll Cardiol,2015,66(9):985

23 Hegbom F,Stavem K,Sire S,et al.Effects of short-term exercise training on symptoms and quality of life in patients with chronic atrial fibrillation[J].Int J Cardiol,2007,116(1):86

24 Osbak PS,Mourier M,Kjaer A,et al.A randomized study of the effects of exercise training on patients with atrial fibrillation[J].Am Heart J,2011,162(6):1 080

25 Malmo V,Nes BM,Amundsen BH,et al.Aerobic interval training reduces the burden of atrial fibrillation in the short term:a randomized trial[J].Circulation,2016,133(5):466

26 Oesterle A,Giancaterino S,Van Noord MG,et al.Effects of supervised exercise training on atrial fibrillation:a meta-analysis of randomized controlled trials[J].J Cardiopulm Rehabil Prev,2022,42(4):258

27 Elliott AD,Verdicchio CV,Mahajan R,et al.An exercise and physical activity program in patients with atrial fibrillation:the ACTIVE-AF randomized controlled trial[J].JACC Clin Electrophysiol,2023,9(4):455

28 Voskoboinik A,Kalman JM,De Silva A,et al.Alcohol abstinence in drinkers with atrial fibrillation[J].N Engl J Med,2020,382(1):20

29 Holmqvist F,Guan N,Zhu Z,et al.Impact of obstructive sleep apnea and continuous positive airway pressure therapy on outcomes in patients with atrial fibrillation-results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)[J].Am Heart J,2015,169(5):647

30 Fein AS,Shvilkin A,Shah D,et al.Treatment of obstructive sleep apnea reduces the risk of atrial fibrillation recurrence after catheter ablation[J].J Am Coll Cardiol,2013,62(4):300

31 Li L,Wang ZW,Li J,et al.Efficacy of catheter ablation of atrial fibrillation in patients with obstructive sleep apnoea with and without continuous positive airway pressure treatment:a meta-analysis of observational studies[J].Europace,2014,16(9):1 309

32 Naruse Y,Tada H,Satoh M,et al.Concomitant obstructive sleep apnea increases the recurrence of atrial fibrillation following radiofrequency catheter ablation of atrial fibrillation:clinical impact of continuous positive airway pressure therapy[J].Heart Rhythm,2013,10(3):331

33 Qureshi WT,Nasir UB,Alqalyoobi S,et al.Meta-analysis of continuous positive airway pressure as a therapy of atrial fibrillation in obstructive sleep apnea[J].Am J Cardiol,2015,116(11):1 767

34 Shukla A,Aizer A,Holmes D,et al.Effect of obstructive sleep apnea treatment on atrial fibrillation recurrence:a meta-analysis[J].JACC Clin Electrophysiol,2015,1(1-2):41

35 Nalliah CJ,Wong GR,Lee G,et al.Impact of CPAP on the atrial fibrillation substrate in obstructive sleep apnea:the SLEEP-AF study[J].JACC Clin Electrophysiol,2022,8(7):869

36 Kadhim K,Middeldorp ME,Elliott AD,et al.Self-reported daytime sleepiness and sleep-disordered breathing in patients with atrial fibrillation:SNOozE-AF[J] Can J Cardiol,2019,35(11):1 457

37 Traaen GM,Overland B,Aakeroy L,et al.Prevalence,risk factors,and type of sleep apnea in patients with paroxysmal atrial fibrillation[J].Int J Cardiol Heart Vasc,2020,26:100 447

38 Kadhim K,Middeldorp ME,Elliott AD,et al.Prevalence and assessment of sleep-disordered breathing in patients with atrial fibrillation:a systematic review and meta-analysis[J].Can J Cardiol,2021,37(11):1 846

39 Chung S,Kim TH,Uhm JS,et al.Stroke and systemic embolism and other adverse outcomes of heart failure with preserved and reduced ejection fraction in patients with atrial fibrillation (from the COmparison study of Drugs for symptom control and complication prEvention of Atrial Fibrillation [CODE-AF])[J].Am J Cardiol,2020,125(1):68

40 Uhm JS,Kim J,Yu HT,et al.Stroke and systemic embolism in patients with atrial fibrillation and heart failure according to heart failure type[J].ESC Heart Fail,2021,8(2):1 582

41 McMurray JJ,Ezekowitz JA,Lewis BS,et al.Left ventricular systolic dysfunction,heart failure,and the risk of stroke and systemic embolism in patients with atrial fibrillation:insights from the ARISTOTLE trial[J].Circ Heart Fail,2013,6(3):451

42 McEvoy JW,Touyz RM,McCarthy CP,et al.2024 ESC Guidelines for the management of elevated blood pressure and hypertension[J].Eur Heart J,2024,https://doi.org/10.1093/eurheartj/ehae178

43 Kim D,Yang PS,Kim TH,et al.Ideal blood pressure in patients with atrial fibrillation[J].J Am Coll Cardiol,2018,72(11):1 233

44 Lip GY,Clementy N,Pericart L,et al.Stroke and major bleeding risk in elderly patients aged ≥75 years with atrial fibrillation:the Loire valley atrial fibrillation project[J].Stroke,2015,46(1):143

45 American Diabetes Association Professional Practice Committee.2.Classification and diagnosis of diabetes:standards of medical care in diabetes-2022[J].Diabetes Care,2022,45(Suppl 1):S17

46 Steensig K,Olesen KKW,Thim T,et al.Should the presence or extent of coronary artery disease be quantified in the CHA2DS2-VASc score in atrial fibrillation?A report from the western Denmark heart registry[J].Thromb Haemost,2018,118(12):2 162

47 Zabalgoitia M,Halperin JL,Pearce LA,et al.Transesophageal echocardiographic correlates of clinical risk of thromboembolism in nonvalvular atrial fibrillation.Stroke prevention in atrial fibrillation III investigators[J].J Am Coll Cardiol,1998,31(7):1 622

48 Stroke Prevention in Atrial Fibrillation Investigators Committee on Echocardiography.Transesophageal echocardiography in atrial fibrillation:standards for acquisition and interpretation and assessment of interobserver variability.Stroke prevention in atrial fibrillation investigators committee on echocardiography[J].J Am Soc Echocardiogr,1996,9(4):556

49 Tomasdottir M,Friberg L,Hijazi Z,et al.Risk of ischemic stroke and utility of CHA2DS2 -VASc score in women and men with atrial fibrillation[J].Clin Cardiol,2019,42(10):1 003

50 Wu VC,Wu M,Aboyans V,et al.Female sex as a risk factor for ischaemic stroke varies with age in patients with atrial fibrillation[J].Heart,2020,106(7):534

51 Mikkelsen AP,Lindhardsen J,Lip GY,et al.Female sex as a risk factor for stroke in atrial fibrillation:a nationwide cohort study[J].J Thromb Haemost,2012,10(9):1 745

52 Antonenko K,Paciaroni M,Agnelli G,et al.Sex-related differences in risk factors,type of treatment received and outcomes in patients with atrial fibrillation and acute stroke:results from the RAF study (early recurrence and cerebral bleeding in patients with acute ischemic stroke and atrial fibrillation)[J].Eur Stroke J,2017,2(1):46

53 Mobley AR,Subramanian A,Champsi A,et al.Thromboembolic events and vascular dementia in patients with atrial fibrillation and low apparent stroke risk[J].Nat Med,2024,30(8):2 288

54 Wang X,Mobley AR,Tica O,et al.Systematic approach to outcome assessment from coded electronic healthcare records in the DaRe2THINK NHS-embedded randomized trial[J].Eur Heart J Digit Health,2022,3(3):426

55 Rivard L,Khairy P,Talajic M,et al.Blinded randomized trial of anticoagulation to prevent ischemic stroke and neurocognitive impairment in atrial fibrillation (BRAIN-AF):methods and design[J].Can J Cardiol,2019,35(8):1 069

56 Hart RG,Pearce LA,Aguilar MI.Meta-analysis:antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation[J].Ann Intern Med,2007,146(12):857

57 Ruff CT,Giugliano RP,Braunwald E,et al.Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation:a meta-analysis of randomised trials[J].Lancet,2014,383(9921):955

58 Lozier MR,Sanchez AM,Lee JJ,et al.Thromboembolic outcomes of different anticoagulation strategies for patients with atrial fibrillation in the setting of hypertrophic cardiomyopathy:a systematic review[J].J Atr Fibrillation,2019,12(4):2 207

59 Guttmann OP,Rahman MS,O’Mahony C,et al.Atrial fibrillation and thromboembolism in patients with hypertrophic cardiomyopathy:systematic review[J].Heart,2014,100(6):465

60 Guttmann OP,Pavlou M,O’Mahony C,et al.Prediction of thromboembolic risk in patients with hypertrophic cardiomyopathy (HCM risk-CVA)[J].Eur J Heart Fail,2015,17(8):837

61 Vilches S,Fontana M,Gonzalez-Lopez E,et al.Systemic embolism in amyloid transthyretin cardiomyopathy[J].Eur J Heart Fail,2022,24(8):1 387

62 Lee SE,Park JK,Uhm JS,et al.Impact of atrial fibrillation on the clinical course of apical hypertrophic cardiomyopathy[J].Heart,2017,103(19):1 496

63 Hirota T,Kubo T,Baba Y,et al.Clinical profile of thromboembolic events in patients with hypertrophic cardiomyopathy in a regional Japanese cohort–results from Kochi RYOMA study[J].Circ J,2019,83(8):1 747

64 Hsu JC,Huang YT,Lin LY.Stroke risk in hypertrophic cardiomyopathy patients with atrial fibrillation:a nationwide database study[J].Aging (Albany NY),2020,12(23):24 219

65 Chao TF,Lip GYH,Liu CJ,et al.Relationship of aging and incident comorbidities to stroke risk in patients with atrial fibrillation[J].J Am Coll Cardiol,2018,71(2):122

66 Weijs B,Dudink E,de Vos CB,et al.Idiopathic atrial fibrillation patients rapidly outgrow their low thromboembolic risk:a 10-year follow-up study[J].Neth Heart J,2019,27(10):487

67 Bezabhe WM,Bereznicki LR,Radford J,et al.Stroke risk reassessment and oral anticoagulant initiation in primary care patients with atrial fibrillation:A ten-year follow-up[J].Eur J Clin Invest,2021,51(6):e13 489

68 Fauchier L,Bodin A,Bisson A,et al.Incident comorbidities,aging and the risk of stroke in 608,108 patients with atrial fibrillation:a nationwide analysis[J].J Clin Med,2020,9(4):1 234

69 Kirchhof P,Toennis T,Goette A,et al.Anticoagulation with edoxaban in patients with atrial high-rate episodes[J].N Engl J Med,2023,389(13):1 167

70 Healey JS,Lopes RD,Granger CB,et al.Apixaban for stroke prevention in subclinical atrial fibrillation[J].N Engl J Med,2024,390(2):107

71 Connolly SJ,Eikelboom J,Joyner C,et al.Apixaban in patients with atrial fibrillation[J].N Engl J Med,2011,364(9):806

72 van Walraven C,Hart RG,Singer DE,et al.Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation:an individual patient meta-analysis[J].JAMA,2002,288(19):2 441

73 Hart RG,Pearce LA,Rothbart RM,et al.Stroke with intermittent atrial fibrillation:incidence and predictors during aspirin therapy.Stroke prevention in atrial fibrillation investigators[J].J Am Coll Cardiol,2000,35(1):183

74 Nieuwlaat R,Dinh T,Olsson SB,et al.Should we abandon the common practice of withholding oral anticoagulation in paroxysmal atrial fibrillation[J]?Eur Heart J,2008,29(7):915

75 Hess PL,Sheng S,Matsouaka R,et al.Strict versus lenient versus poor rate control among patients with atrial fibrillation and heart failure (from the get with the guidelines—heart failure program)[J].Am J Cardiol,2020,125(6):894

76 Van Gelder IC,Groenveld HF,Crijns HJ,et al.Lenient versus strict rate control in patients with atrial fibrillation[J].N Engl J Med,2010,362(15):1 363

77 Olshansky B,Rosenfeld LE,Warner AL,et al.The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study:approaches to control rate in atrial fibrillation[J].J Am Coll Cardiol,2004,43(7):1 201

78 Kotecha D,Bunting KV,Gill SK,et al.Effect of digoxin vs bisoprolol for heart rate control in atrial fibrillation on patient-reported quality of life:the RATE-AF randomized clinical trial[J].JAMA,2020,324(24):2 497

79 Ulimoen SR,Enger S,Carlson J,et al.Comparison of four single-drug regimens on ventricular rate and arrhythmia-related symptoms in patients with permanent atrial fibrillation[J].Am J Cardiol,2013,111(2):225

80 Tisdale JE,Padhi ID,Goldberg AD,et al.A randomized,double-blind comparison of intravenous diltiazem and digoxin for atrial fibrillation after coronary artery bypass surgery[J].Am Heart J,1998,135(5 Pt 1):739

81 Brignole M,Pokushalov E,Pentimalli F,et al.A randomized controlled trial of atrioventricular junction ablation and cardiac resynchronization therapy in patients with permanent atrial fibrillation and narrow QRS[J].Eur Heart J,2018,39(45):3 999

82 Brignole M,Pentimalli F,Palmisano P,et al.AV junction ablation and cardiac resynchronization for patients with permanent atrial fibrillation and narrow QRS:the APAF-CRT mortality trial[J].Eur Heart J,2021,42(46):4 731

83 Hocini M,Sanders P,Deisenhofer I,et al.Reverse remodeling of sinus node function after catheter ablation of atrial fibrillation in patients with prolonged sinus pauses[J].Circulation,2003,108(10):1 172

84 Inada K,Yamane T,Tokutake K,et al.The role of successful catheter ablation in patients with paroxysmal atrial fibrillation and prolonged sinus pauses:outcome during a 5-year follow-up[J].Europace,2014,16(2):208

85 Chen YW,Bai R,Lin T,et al.Pacing or ablation:which is better for paroxysmal atrial fibrillation-related tachycardia-bradycardia syndrome[J]?Pacing Clin Electrophysiol,2014,37(4):403

86 Zhang R,Wang Y,Yang M,et al.Risk stratification for atrial fibrillation and outcomes in tachycardia-bradycardia syndrome:ablation vs.pacing[J].Front Cardiovasc Med,2021,8:674 471

87 Zhang XD,Gu J,Jiang WF,et al.Optimal rhythm-control strategy for recurrent atrial tachycardia after catheter ablation of persistent atrial fibrillation:a randomized clinical trial[J].Eur Heart J,2014,35(20):1 327

88 Zhou L,He L,Wang W,et al.Effect of repeat catheter ablation vs.antiarrhythmic drug therapy among patients with recurrent atrial tachycardia/atrial fibrillation after atrial fibrillation catheter ablation:data from CHINA-AF registry[J].Europace,2023,25(2):382

89 Fink T,Metzner A,Willems S,et al.Procedural success,safety and patients satisfaction after second ablation of atrial fibrillation in the elderly:results from the German ablation registry[J].Clin Res Cardiol,2019,108(12):1 354

90 Wilber DJ,Pappone C,Neuzil P,et al.Comparison of antiarrhythmic drug therapy and radiofrequency catheter ablation in patients with paroxysmal atrial fibrillation:a randomized controlled trial[J].JAMA,2010,303(4):333

91 Calkins H,Reynolds MR,Spector P,et al.Treatment of atrial fibrillation with antiarrhythmic drugs or radiofrequency ablation:two systematic literature reviews and meta-analyses[J].Circ Arrhythm Electrophysiol,2009,2(4):349

92 Jais P,Cauchemez B,Macle L,et al.Catheter ablation versus antiarrhythmic drugs for atrial fibrillation:the A4 study[J].Circulation 2008;118(24):2 498

93 Packer DL,Kowal RC,Wheelan KR,et al.Cryoballoon ablation of pulmonary veins for paroxysmal atrial fibrillation:first results of the North American Arctic Front (STOP AF) pivotal trial[J].J Am Coll Cardiol,2013,61(16):1 713

94 Poole JE,Bahnson TD,Monahan KH,et al.Recurrence of atrial fibrillation after catheter ablation or antiarrhythmic drug therapy in the CABANA trial[J].J Am Coll Cardiol,2020,75(25):3 105

95 Mont L,Bisbal F,Hernandez-Madrid A,et al.Catheter ablation vs.antiarrhythmic drug treatment of persistent atrial fibrillation:a multicentre,randomized,controlled trial (SARA study)[J].Eur Heart J,2014,35(8):501

96 Scherr D,Khairy P,Miyazaki S,et al.Five-year outcome of catheter ablation of persistent atrial fibrillation using termination of atrial fibrillation as a procedural endpoint[J].Circ Arrhythm Electrophysiol,2015,8(1):18

97 Morillo CA,Verma A,Connolly SJ,et al.Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of paroxysmal atrial fibrillation (RAAFT-2):a randomized trial[J].JAMA,2014,311(7):692

98 Oral H,Pappone C,Chugh A,et al.Circumferential pulmonary-vein ablation for chronic atrial fibrillation[J].N Engl J Med,2006,354(9):934

99 Yan Huo TG,Sch?nbauer R,Wójcik M,et al.Low-voltage myocardium-guided ablation trial of persistent atrial fibrillation[J].NEJM Evid,2022,1(11):EVIDoa2 200 141

100 Reddy VY,Gerstenfeld EP,Natale A,et al.Pulsed field or conventional thermal ablation for paroxysmal atrial fibrillation[J].N Engl J Med,2023,389(18):1 660

101 Heijman J,Linz D,Schotten U.Dynamics of atrial fibrillation mechanisms and comorbidities[J].Annu Rev Physiol,2021,83:83

102 Fabritz L,Crijns H,Guasch E,et al.Dynamic risk assessment to improve quality of care in patients with atrial fibrillation:the 7th AFNET/EHRA consensus conference[J].Europace,2021,23(3):329

103 Brandes A,Smit MD,Nguyen BO,et al.Risk factor management in atrial fibrillation[J].Arrhythm Electrophysiol Rev,2018,7(2):118